ArticleExperimental and therapeutic medicine2021

Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials.

Yuxin Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.